The assessment of benefits and harms and their relative importance for patients, industry and agencies: How should they be captured? 2-3 April 2014, Surrey, UK This workshop focused on [...]
Benefit-risk assessment in the post-approval period: How to ensure a life cycle approach to evaluating benefits and risks 12-13 June 2014, Washington DC, USA The discussion at this workshop [...]
IS THERE A COMMONALITY ACROSS THE STRUCTURED DECISION FRAMEWORKS USED BY HTA AND REGULATORY AGENCIES? 1st-2nd October 2013, Surrey, UK This Workshop was designed to bring together the various [...]
Building quality into HTA/coverage decision-making processes: What are the features of good practice in HTA? 2-3 December 2013, Heathrow, UK This workshop continued the work of the CIRS September [...]
Focus on Latin America: Building quality submission and review processes and practices - Overcoming challenges and meeting expectations 23-24 January 2014, Lima, Peru This workshop was held to discuss [...]
Implementing an internationally accepted framework for the benefit-risk assessment of medicines: How close are we to this objective? 20-21 June 2013, Washington DC, USA At the annual CIRS Benefit-Risk [...]
Patient voice in clinical development: Can patients contribute to the benefit-risk assessment of new medicines? 13-14 March 2013, Surrey, UK The consensus of the April 2012 CIRS Workshop, The [...]
Regulatory review: How do agencies ensure the quality of the decision? The role of decision frameworks in the review of new medicines: What are the challenges and solutions that [...]
Building the benefit-risk toolbox: Are there enough common elements across the different methodologies to enable a consensus on a scientifically acceptable framework for making benefit-risk decisions? 20-21 June 2012, [...]
The patient's role in the benefit-risk assessment for the submission and review of new medicines 25-26 April 2012, Hampshire, UK This workshop gained a perspective from various stakeholders in [...]
